ArticleIJID regions2026
Clinical approach to drug-resistant tuberculosis of the brain and spine in a low-income setting: A case series.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (TB) of the brain and spine is difficult to sample for culture. It poses a significant challenge to physicians in low- and middle-income countries. Methods: We present three patients of drug-resistant tuberculosis and demonstrate how we manage them in limited resources. Case Series: Multi drug-resistant (MDR1): a young female patient had cerebellar tuberculomas at presentation. While being on conventional antituberculous therapy (ATT), she developed meningitis, and deteriorated with impaired conscious-level. Later, patient sustained ischemic strokes. Second-line ATT improved her condition. Treatment course was complicated by peripheral neuropathy, and psychotic behavior.MDR2, a middle-aged woman having type-II diabetes was diagnosed with lumbar spondylitis. She was on conventional ATT for 1 year. Severe backache relapsed within a month of discontinuation of treatment. We started her on empirical second-line treatment. She had a dramatic response in pain and completely recovered at 1 year.MDR3, a middle-aged woman had spondylitic changes at D10-D11 vertebral bodies on magnetic resonance imaging. The pain showed sub-optimum response to conventional ATT. The hyperintense signal changes resolved at 1 year of treatment with levofloxacin and linezolid. Conclusion: These outcomes will raise physicians' awareness of the need for early suspicion, and timely initiation of second-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.